Login to Your Account



PHASE II FAILED, BUT . . .

Culture club: FDA gets aboard with Arikayce in Insmed's NTM bid

By Randy Osborne
Staff Writer

Thursday, June 19, 2014
Insmed Inc.'s eventful ride with Arikayce (inhaled liposomal amikacin) took an upswing with word from the FDA that the compound has achieved breakthrough designation in nontuberculous mycobacterial (NTM) lung disease, despite missing its primary endpoint in a phase II trial in that indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription